Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis
- 1 February 1996
- journal article
- clinical trial
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 64 (2), 193-200
- https://doi.org/10.1016/0165-5728(95)00176-x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitisEuropean Journal of Neurology, 1994
- Lymphocyte responses and cytokinesCell, 1994
- Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis ratsEuropean Journal of Immunology, 1993
- Cytokine regulation of T-cell function: potential for therapeutic interventionImmunology Today, 1993
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma.The Journal of Experimental Medicine, 1993
- Immunological Aspects of Demyelinating DiseasesAnnual Review of Immunology, 1992
- A new view of prostaglandin E regulation of the immune responseImmunology Today, 1991
- T‐lymphocyte entry into the central nervous systemJournal of Neuroscience Research, 1991
- PentoxifyllineDrugs, 1987